MedPath

Role of Inflammation in Carpal Tunnel Syndrome

Not yet recruiting
Conditions
Median Neuropathy, Carpal Tunnel
Carpal Tunnel Syndrome
Registration Number
NCT05852288
Lead Sponsor
Ahram Canadian University
Brief Summary

This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Individuals aged 18 years or older
  • Diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies
  • Willingness and ability to provide informed consent to participate in the study
  • Willingness and ability to comply with study procedures and follow-up visits
Exclusion Criteria
  • Presence of other neurological conditions that may affect nerve function in the upper extremities
  • Use of medications that may affect inflammation or carpal tunnel syndrome severity
  • History of previous carpal tunnel release surgery on the affected wrist
  • Inability to comply with study procedures or follow-up visits
  • Pregnancy or breastfeeding

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The relationship between inflammatory markers and pinch strength of CTS patients.Changes of inflammatory markers and pinch strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

interleukin-6, tumor necrosis factor-alpha using blood tests. pinch strength will be measured using a dynamometer

The relationship between inflammatory markers and nerve conduction study of patients with CTSChanges of inflammatory markers and nerve conduction study at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

interleukin-6, tumor necrosis factor-alpha using blood tests. Nerve conduction study results (motor and sensory distal latency of median nerve and amplitude) will be used to determine CTS severity based on Bland's grading scale.

The relationship between inflammatory markers and symptom severity of carpal tunnel syndrome (CTS).Changes of inflammatory markers and symptoms severity at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

interleukin-6, tumor necrosis factor-alpha using blood tests. Symptom severity will be assessed with standardized questionnaire "the Boston Carpal Tunnel Questionnaire".

The relationship between inflammatory markers and grip strength of patients with CTS.Changes of inflammatory markers and grip strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

interleukin-6, tumor necrosis factor-alpha using blood tests. functional status by grip strength using a dynamometer.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Outpatient clinic of faculty of physical therapy, Ahram Canadian University

🇪🇬

Al Ḩayy Ath Thāmin, Giza, Egypt

Outpatient clinic of faculty of physical therapy, Ahram Canadian University
🇪🇬Al Ḩayy Ath Thāmin, Giza, Egypt

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.